Compare Novo Nordisk A/S (NVO) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Oklo Inc — how do they compare? Novo Nordisk A/S trades at $38.48 (market cap $165.31B), while Oklo Inc trades at $34.55 (market cap $6.43B). The key difference: Novo Nordisk A/S is far larger — about 25.7× Oklo Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Oklo Inc for 32 Days on average.
| NVO | OKLO | |
|---|---|---|
Market Cap | $165.31B | $6.43B |
Volume | 11,432,838 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $63.98 | $174.14 |
52-Week Low | $35.29 | $34.57 |
Typical Hold Time | 116 Days | 32 Days |
Enterprise Value | $179.56B | $3.97B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
OKLO trades at $34.65, down 5.91% today, with a bearish technical signal from moving averages. The company shows no revenue in 2025 and negative net income of -$105.66M, with profitability metrics deeply negative. Analyst consensus remains strongly bullish with a $78.63 price target, but recent news highlights competitive pressures and dilution concerns from stock sales.
The outlook hinges on OKLO's ability to commercialize its nuclear reactor pipeline. High institutional buy ratings suggest long-term potential, but execution risks, cash burn, and intense competition in the SMR space pose significant challenges. The stock offers speculative growth exposure amid substantial operational and financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
